Analysis of the correlation between the expression levels of the identified hub genes and prognosis following ICI therapy revealed the potential of this gene set as a predictor of response to anti-PD-1 and anti-PD-L1 treatments across more than 15 tumor types available in the ROC-Immunotherapy Plotter tool. This evidence concerns the gene CD274 and neoplasm.